Modeling mania in preclinical settings: A comprehensive review

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 66, Issue , 2016, Pages 22-34

  Sharma, Ajaykumar N ^a   Fries, Gabriel R ^a   Galvez, Juan F ^b   Valvassori, Samira S ^c   Soares, Jair C ^a   Carvalho, André F ^d   Quevedo, Joao ^a,c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Facultad de Medicina   (Colombia)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

^d FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

Animal models; Mania; Mood disorders; Neuroprogression; Preclinical models; Psychiatry; Treatment resistance

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLERA TOXIN; CIRCADIAN RHYTHM SIGNALING PROTEIN; DOPAMINE TRANSPORTER; GLUTAMATE RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; KETAMINE; MITOGEN ACTIVATED PROTEIN KINASE; NEURON SPECIFIC ALPHA 3 SUBUNIT PROTEIN; NEURON SPECIFIC NUCLEAR PROTEIN; OUABAIN; POSTSYNAPTIC DENSITY PROTEIN 95; POSTSYNAPTIC DENSITY PROTEIN SHANK3; PROTEIN BCL 2; PSYCHOSTIMULANT AGENT; QUINPIROLE; TRANSCRIPTION FACTOR CLOCK; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL MODEL; BIPOLAR DISORDER; BIPOLAR MANIA; CONSTRUCT VALIDITY; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DISEASE COURSE; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL FACTOR; ENZYME ACTIVITY; EXPERIMENTAL HYPERACTIVITY; EXTERNAL VALIDITY; FACE VALIDITY; GLUCOSE TRANSPORT; HEREDITY; HYPERACTIVITY; MANIA; MOOD DISORDER; MOUSE; NEUROTRANSMISSION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSTSYNAPTIC DENSITY; PREDICTIVE VALIDITY; RESIDENT-INTRUDER TEST; REVIEW; SIGNAL TRANSDUCTION; SLEEP DEPRIVATION; SYNAPSE; ANIMAL; BRAIN; DISEASE MODEL; GENE EXPRESSION;

ANIMALS; BIPOLAR DISORDER; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION;

EID: 84946962812     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2015.11.001     Document Type: Review

References (212)

1. Adamec R.E. Amygdala kindling and anxiety in the rat. Neuroreport 1990, 1:255-258.
2. Agam G., Bersudsky Y., Berry G.T., Moechars D., Lavi-Avnon Y., Belmaker R.H. Knockout mice in understanding the mechanism of action of lithium. Biochem. Soc. Trans. 2009, 37:1121-1125.
3. American Psychiatric Association, American Psychiatric Association.DSM-5 Task Force., PsychiatryOnline (Online service) Diagnostic and Statistical Manual of Mental Disorders : DSM-5 2013, American Psychiatric Association, Washington, D.C., (pp. xliv, 947 p.). 5th ed.
4. Arban R., Maraia G., Brackenborough K., Winyard L., Wilson A., Gerrard P., Large C. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania. Behav. Brain Res. 2005, 158:123-132.
5. Arent C.O., Valvassori S.S., Fries G.R., Stertz L., Ferreira C.L., Lopes-Borges J., Mariot E., Varela R.B., Ornell F., Kapczinski F., Andersen M.L., Quevedo J. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol. Neurobiol. 2011, 43:207-214.
6. Arey R., McClung C.A. An inhibitor of casein kinase 1 epsilon/delta partially normalizes the manic-like behaviors of the ClockDelta19 mouse. Behav. Pharmacol. 2012, 23:392-396.
7. Armani F., Andersen M.L., Andreatini R., Frussa-Filho R., Tufik S., Galduroz J.C. Successful combined therapy with tamoxifen and lithium in a paradoxical sleep deprivation-induced mania model. CNS Neurosci. Ther. 2012, 18:119-125.
8. Armani F., Andersen M.L., Galduroz J.C. Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology 2014, 231:639-649.
9. Bachevalier J. Brief report: medial temporal lobe and autism: a putative animal model in primates. J. Autism Dev. Disord. 1996, 26:217-220.
10. +-ATPase activity and lipid peroxidation in bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2012, 37:56-61.
11. Bannerman D.M., Yee B.K., Good M.A., Heupel M.J., Iversen S.D., Rawlins J.N. Double dissociation of function within the hippocampus: a comparison of dorsal, ventral, and complete hippocampal cytotoxic lesions. Behav. Neurosci. 1999, 113:1170-1188.
12. Bannerman D.M., Lemaire M., Beggs S., Rawlins J.N., Iversen S.D. Cytotoxic lesions of the hippocampus increase social investigation but do not impair social-recognition memory. Exp. Brain Res. 2001, 138:100-109.
13. Baptista T., Weiss S.R., Post R.M. Carbamazepine attenuates cocaine-induced increases in dopamine in the nucleus accumbens: an in vivo dialysis study. Eur. J. Pharmacol. 1993, 236:39-42.
14. Belzung C., Lemoine M. Criteria of validity for animal models of psychiatric disorders: focus on anxiety disorders and depression. Biol. Mood Anxiety Disord. 2011, 1:9.
15. Benedetti F., Fresi F., Maccioni P., Smeraldi E. Behavioural sensitization to repeated sleep deprivation in a mice model of mania. Behav. Brain Res. 2008, 187:221-227.
16. Benedetti F., Riccaboni R., Dallaspezia S., Locatelli C., Smeraldi E., Colombo C. Effects of CLOCK gene variants and early stress on hopelessness and suicide in bipolar depression. Chronobiol. Int. 2015, 1-6.
17. Beneyto M., Kristiansen L.V., Oni-Orisan A., McCullumsmith R.E., Meador-Woodruff J.H. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 2007, 32:1888-1902.
18. Berggren U., Tallstedt L., Ahlenius S., Engel J. The effect of lithium on amphetamine-induced locomotor stimulation. Psychopharmacology 1978, 59:41-45.
19. Berk M. Neuroprogression: pathways to progressive brain changes in bipolar disorder. Int. J. Neuropsychopharmacol. 2009, 12:441-445.
20. Berk M., Dodd S., Kauer-Sant'anna M., Malhi G.S., Bourin M., Kapczinski F., Norman T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl. 2007, 41-49.
21. Berk M., Kapczinski F., Andreazza A.C., Dean O.M., Giorlando F., Maes M., Yucel M., Gama C.S., Dodd S., Dean B., Magalhaes P.V., Amminger P., McGorry P., Malhi G.S. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 2011, 35:804-817.
22. Bersudsky Y., Shaldubina A., Kozlovsky N., Woodgett J.R., Agam G., Belmaker R.H. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav. Pharmacol. 2008, 19:217-224.
23. Brocardo P.S., Budni J., Pavesi E., Franco J.L., Uliano-Silva M., Trevisan R., Terenzi M.G., Dafre A.L., Rodrigues A.L. Folic acid administration prevents ouabain-induced hyperlocomotion and alterations in oxidative stress markers in the rat brain. Bipolar Disord. 2010, 12:414-424.
24. Bruning C.A., Prigol M., Luchese C., Pinton S., Nogueira C.W. Diphenyl diselenide ameliorates behavioral and oxidative parameters in an animal model of mania induced by ouabain. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2012, 38:168-174.
25. Budni J., Valvassori S.S., Quevedo J. Biological mechanisms underlying neuroprogression in bipolar disorder. Rev. Bras. Psiquiatr. 2013, 35:1-2.
26. Cappeliez P., Moore E. Effects of lithium on an amphetamine animal model of bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1990, 14:347-358.
27. Cassidy F., Ahearn E., Carroll B.J. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am. J. Psychiatry 1999, 156:1417-1420.
28. Cechinel-Recco K., Valvassori S.S., Varela R.B., Resende W.R., Arent C.O., Vitto M.F., Luz G., de Souza C.T., Quevedo J. Lithium and tamoxifen modulate cellular plasticity cascades in animal model of mania. J. Psychopharmacol. 2012, 26:1594-1604.
29. Chen C., Zhang C., Cheng L., Reilly J.L., Bishop J.R., Sweeney J.A., Chen H.Y., Gershon E.S., Liu C. Correlation between DNA methylation and gene expression in the brains of patients with bipolar disorder and schizophrenia. Bipolar Disord. 2014, 16:790-799.
30. Chiu C.T., Scheuing L., Liu G., Liao H.M., Linares G.R., Lin D., Chuang D.M. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. Int. J. Neuropsychopharmacol. 2014, 18.
31. Christo P.J., El-Mallakh R.S. Possible role of endogenous ouabain-like compounds in the pathophysiology of bipolar illness. Med. Hypotheses 1993, 41:378-383.
32. Coque L., Mukherjee S., Cao J.L., Spencer S., Marvin M., Falcon E., Sidor M.M., Birnbaum S.G., Graham A., Neve R.L., Gordon E., Ozburn A.R., Goldberg M.S., Han M.H., Cooper D.C., McClung C.A. Specific role of VTA dopamine neuronal firing rates and morphology in the reversal of anxiety-related, but not depression-related behavior in the ClockDelta19 mouse model of mania. Neuropsychopharmacology 2011, 36:1478-1488.
33. Cunha A.B., Frey B.N., Andreazza A.C., Goi J.D., Rosa A.R., Goncalves C.A., Santin A., Kapczinski F. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes. Neurosci. Lett. 2006, 398:215-219.
34. Damri O., Sade Y., Toker L., Bersudsky Y., Belmaker R.H., Agam G., Azab A.N. Molecular effects of lithium are partially mimicked by inositol-monophosphatase (IMPA)1 knockout mice in a brain region-dependent manner. Eur. Neuropsychopharmacol. 2015, 25:425-434.
35. 2-like receptor agonist quinpirole. Eur. J. Pharmacol. 2000, 395:157-160.
36. 2-like receptor agonist quinpirole. Eur. J. Pharmacol. 2001, 416:107-111.
37. 2-like receptor agonist quinpirole. Eur. J. Pharmacol. 2006, 535:208-211.
38. Davies C., Sanger D.J., Steinberg H., Tomkiewicz M., U'Prichard D.C. Lithium and alpha-methyl-p-tyrosine prevent "manic" activity in rodents. Psychopharmacologia 1974, 36:263-274.
39. Dencker D., Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav. Brain Res. 2010, 207:78-83.
40. Dickerson F., Stallings C., Vaughan C., Origoni A., Khushalani S., Yolken R. Antibodies to the glutamate receptor in mania. Bipolar Disord. 2012, 14:547-553.
41. Dzirasa K., Covington H.E. Increasing the validity of experimental models for depression. Ann. N. Y. Acad. Sci. 2012, 1265:36-45.
42. Dzirasa K., McGarity D.L., Bhattacharya A., Kumar S., Takahashi J.S., Dunson D., McClung C.A., Nicolelis M.A. Impaired limbic gamma oscillatory synchrony during anxiety-related behavior in a genetic mouse model of bipolar mania. J. Neurosci. 2011, 31:6449-6456.
43. Einat H. Modelling facets of mania-new directions related to the notion of endophenotypes. J. Psychopharmacol. 2006, 20:714-722.
44. Einat H. Different behaviors and different strains: potential new ways to model bipolar disorder. Neurosci. Biobehav. Rev. 2007, 31:850-857.
45. Einat H. Establishment of a battery of simple models for facets of bipolar disorder: a practical approach to achieve increased validity, better screening and possible insights into endophenotypes of disease. Behav. Genet. 2007, 37:244-255.
46. Einat H. Strategies for the development of animal models for bipolar disorder: new opportunities and new challenges. Curr. Top. Behav. Neurosci. 2011, 5:69-87.
47. Einat H. New ways of modeling bipolar disorder. Harv. Rev. Psychiatry 2014, 22:348-352.
48. Einat H. Partial effects of the protein kinase C inhibitor chelerythrine in a battery of tests for manic-like behavior in Black Swiss mice. Pharmacol. Rep. 2014, 66:722-725.
49. Einat H., Manji H.K. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol. Psychiatry 2006, 59:1160-1171.
50. Einat H., Yuan P., Manji H.K. Increased anxiety-like behaviors and mitochondrial dysfunction in mice with targeted mutation of the Bcl-2 gene: further support for the involvement of mitochondrial function in anxiety disorders. Behav. Brain Res. 2005, 165:172-180.
51. el-Mallakh R.S., Wyatt R.J. The Na,K-ATPase hypothesis for bipolar illness. Biol. Psychiatry 1995, 37:235-244.
52. el-Mallakh R.S., Harrison L.T., Li R., Changaris D.G., Levy R.S. An animal model for mania: preliminary results. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 1995, 19:955-962.
53. El-Mallakh R.S., El-Masri M.A., Huff M.O., Li X.P., Decker S., Levy R.S. Intracerebroventricular administration of ouabain as a model of mania in rats. Bipolar Disord. 2003, 5:362-365.
54. El-Mallakh R.S., Decker S., Morris M., Li X.P., Huff M.O., El-Masri M.A., Levy R.S. Efficacy of olanzapine and haloperidol in an animal model of mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2006, 30:1261-1264.
55. Ene H.M., Kara N.Z., Einat H. The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors. Behav. Pharmacol. 2015, 26:331-337.
56. Engel S.R., Creson T.K., Hao Y., Shen Y., Maeng S., Nekrasova T., Landreth G.E., Manji H.K., Chen G. The extracellular signal-regulated kinase pathway contributes to the control of behavioral excitement. Mol. Psychiatry 2009, 14:448-461.
57. Fagiolini A., Kupfer D.J., Houck P.R., Novick D.M., Frank E. Obesity as a correlate of outcome in patients with bipolar I disorder. Am. J. Psychiatry 2003, 160:112-117.
58. Fernandes B.S., Gama C.S., Cereser K.M., Yatham L.N., Fries G.R., Colpo G., de Lucena D., Kunz M., Gomes F.A., Kapczinski F. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis. J. Psychiatr. Res. 2011, 45:995-1004.
59. Flaisher-Grinberg S., Einat H. Strain-specific battery of tests for domains of mania: effects of valproate, lithium and imipramine. Front. Psychol. 2010, 1:10.
60. 2-autoreceptors in regulating dopamine neuron activity and transmission. Neuroscience 2014, 282c:13-22.
61. Frank E., Kupfer D.J., Thase M.E., Mallinger A.G., Swartz H.A., Fagiolini A.M., Grochocinski V., Houck P., Scott J., Thompson W., Monk T. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch. Gen. Psychiatry 2005, 62:996-1004.
62. Fratta W., Collu M., Martellotta M.C., Pichiri M., Muntoni F., Gessa G.L. Stress-induced insomnia: opioid-dopamine interactions. Eur. J. Pharmacol. 1987, 142:437-440.
63. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Valvassori S.S., Reus G.Z., Quevedo J., Kapczinski F. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci. 2006, 79:281-286.
64. Frey B.N., Valvassori S.S., Reus G.Z., Martins M.R., Petronilho F.C., Bardini K., Dal-Pizzol F., Kapczinski F., Quevedo J. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiatry Neurosci. 2006, 31:326-332.
65. Fries G.R., Pfaffenseller B., Stertz L., Paz A.V., Dargel A.A., Kunz M., Kapczinski F. Staging and neuroprogression in bipolar disorder. Curr. Psychiatry Rep. 2012, 14:667-675.
66. Fries G.R., Valvassori S.S., Bock H., Stertz L., Magalhaes P.V., Mariot E., Varela R.B., Kauer-Sant'Anna M., Quevedo J., Kapczinski F., Saraiva-Pereira M.L. Memory and brain-derived neurotrophic factor after subchronic or chronic amphetamine treatment in an animal model of mania. J. Psychiatr. Res. 2015.
67. Frye M.A., Salloum I.M. Bipolar disorder and comorbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006, 8:677-685.
68. Galvez J.F., Sanches M., Bauer I.E., Sharma A.N., Hamilton J., Mwangi B., Quevedo J., Zunta-Soares G., Soares J.C. Premorbid obesity and metabolic disturbances as promising clinical targets for the prevention and early screening of bipolar disorder. Med. Hypotheses 2015, 84:285-293.
69. Gao Y., Payne R.S., Schurr A., Hougland T., Lord J., Herman L., Lei Z., Banerjee P., El-Mallakh R.S. Memantine reduces mania-like symptoms in animal models. Psychiatry Res. 2011, 188:366-371.
70. Gardner R. Mechanisms in manic-depressive disorder: an evolutionary model. Arch. Gen. Psychiatry 1982, 39:1436-1441.
71. Gazal M., Valente M.R., Acosta B.A., Kaufmann F.N., Braganhol E., Lencina C.L., Stefanello F.M., Ghisleni G., Kaster M.P. Neuroprotective and antioxidant effects of curcumin in a ketamine-induced model of mania in rats. Eur. J. Pharmacol. 2014, 724:132-139.
72. Geddes J.R., Miklowitz D.J. Treatment of bipolar disorder. Lancet 2013, 381:1672-1682.
73. Gessa G.L., Pani L., Serra G., Fratta W. Animal models of mania. Adv. Biochem. Psychopharmacol. 1995, 49:43-66.
74. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox. Res. 2008, 14:71-78.
75. Ghedim F.V., Fraga Dde B., Deroza P.F., Oliveira M.B., Valvassori S.S., Steckert A.V., Budni J., Dal-Pizzol F., Quevedo J., Zugno A.I. Evaluation of behavioral and neurochemical changes induced by ketamine in rats: implications as an animal model of mania. J. Psychiatr. Res. 2012, 46:1569-1575.
76. Giros B., Jaber M., Jones S.R., Wightman R.M., Caron M.G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379:606-612.
77. Goldstein I., Lax E., Gispan-Herman I., Ovadia H., Rosen H., Yadid G., Lichtstein D. Neutralization of endogenous digitalis-like compounds alters catecholamines metabolism in the brain and elicits anti-depressive behavior. Eur. Neuropsychopharmacol. 2012, 22:72-79.
78. Gould T.D., Einat H. Animal models of bipolar disorder and mood stabilizer efficacy: a critical need for improvement. Neurosci. Biobehav. Rev. 2007, 31:825-831.
79. Gould T.J., Keith R.A., Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav. Brain Res. 2001, 118:95-105.
80. Graff J., Tsai L.H. The potential of HDAC inhibitors as cognitive enhancers. Annu. Rev. Pharmacol. Toxicol. 2013, 53:311-330.
81. Hamani C., Nobrega J.N. Deep brain stimulation in clinical trials and animal models of depression. Eur. J. Neurosci. 2010, 32:1109-1117.
82. Hamani C., Nobrega J.N. Preclinical studies modeling deep brain stimulation for depression. Biol. Psychiatry 2012, 72:916-923.
83. Hamid H., Gao Y., Lei Z., Hougland M.T., El-Mallakh R.S. Effect of ouabain on sodium pump alpha-isoform expression in an animal model of mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2009, 33:1103-1106.
84. Han K., Holder J.L., Schaaf C.P., Lu H., Chen H., Kang H., Tang J., Wu Z., Hao S., Cheung S.W., Yu P., Sun H., Breman A.M., Patel A., Lu H.C., Zoghbi H.Y. SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature 2013, 503:72-77.
85. Hannah-Poquette C., Anderson G.W., Flaisher-Grinberg S., Wang J., Meinerding T.M., Einat H. Modeling mania: further validation for Black Swiss mice as model animals. Behav. Brain Res. 2011, 223:222-226.
86. Hashimoto H., Shintani N., Baba A. New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice. Ann. N. Y. Acad. Sci. 2006, 1070:75-89.
87. Hattori S., Takao K., Tanda K., Toyama K., Shintani N., Baba A., Hashimoto H., Miyakawa T. Comprehensive behavioral analysis of pituitary adenylate cyclase-activating polypeptide (PACAP) knockout mice. Front. Behav. Neurosci. 2012, 6:58.
88. Heinzen E.L., Arzimanoglou A., Brashear A., Clapcote S.J., Gurrieri F., Goldstein D.B., Johannesson S.H., Mikati M.A., Neville B., Nicole S., Ozelius L.J., Poulsen H., Schyns T., Sweadner K.J., van den Maagdenberg A., Vilsen B. Distinct neurological disorders with ATP1A3 mutations. Lancet Neurol. 2014, 13:503-514.
89. Henry B.L., Minassian A., Young J.W., Paulus M.P., Geyer M.A., Perry W. Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci. Biobehav. Rev. 2010, 34:1296-1306.
90. Hicks R.A., Moore J.D., Hayes C., Phillips N., Hawkins J. REM sleep deprivation increases aggressiveness in male rats. Physiol. Behav. 1979, 22:1097-1100.
91. Hoertel N., de Maricourt P., Gorwood P. Novel routes to bipolar disorder drug discovery. Expert Opin. Drug Discovery 2013, 8:907-918.
92. Hougland M.T., Gao Y., Herman L., Ng C.K., Lei Z., El-Mallakh R.S. Positron emission tomography with fluorodeoxyglucose-F18 in an animal model of mania. Psychiatry Res. 2008, 164:166-171.
93. Huff M.O., Li X.P., Ginns E., El-Mallakh R.S. Effect of ethacrynic acid on the sodium- and potassium-activated adenosine triphosphatase activity and expression in Old Order Amish bipolar individuals. J. Affect. Disord. 2010, 123:303-307.
94. Jornada L.K., Moretti M., Valvassori S.S., Ferreira C.L., Padilha P.T., Arent C.O., Fries G.R., Kapczinski F., Quevedo J. Effects of mood stabilizers on hippocampus and amygdala BDNF levels in an animal model of mania induced by ouabain. J. Psychiatr. Res. 2010, 44:506-510.
95. Jornada L.K., Valvassori S.S., Steckert A.V., Moretti M., Mina F., Ferreira C.L., Arent C.O., Dal-Pizzol F., Quevedo J. Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J. Psychiatr. Res. 2011, 45:162-168.
96. Kalinichev M., Dawson L.A. Evidence for antimanic efficacy of glycogen synthase kinase-3 (GSK3) inhibitors in a strain-specific model of acute mania. Int. J. Neuropsychopharmacol. 2011, 14:1051-1067.
97. Kalynchuk L.E. Long-term amygdala kindling in rats as a model for the study of interictal emotionality in temporal lobe epilepsy. Neurosci. Biobehav. Rev. 2000, 24:691-704.
98. Kapczinski F., Dias V.V., Kauer-Sant'Anna M., Frey B.N., Grassi-Oliveira R., Colom F., Berk M. Clinical implications of a staging model for bipolar disorders. Expert. Rev. Neurother. 2009, 9:957-966.
99. Kapczinski F., Dal-Pizzol F., Teixeira A.L., Magalhaes P.V., Kauer-Sant'Anna M., Klamt F., Moreira J.C., de Bittencourt Pasquali M.A., Fries G.R., Quevedo J., Gama C.S., Post R. Peripheral biomarkers and illness activity in bipolar disorder. J. Psychiatr. Res. 2011, 45:156-161.
100. Kapczinski F., Magalhaes P.V., Balanza-Martinez V., Dias V.V., Frangou S., Gama C.S., Gonzalez-Pinto A., Grande I., Ha K., Kauer-Sant'Anna M., Kunz M., Kupka R., Leboyer M., Lopez-Jaramillo C., Post R.M., Rybakowski J.K., Scott J., Strejilevitch S., Tohen M., Vazquez G., Yatham L., Vieta E., Berk M. Staging systems in bipolar disorder: an International Society for Bipolar Disorders Task Force Report. Acta Psychiatr. Scand. 2014, 130:354-363.
101. Kaplan K.A., Harvey A.G. Behavioral treatment of insomnia in bipolar disorder. Am. J. Psychiatry 2013, 170:716-720.
102. Kara N.Z., Einat H. Rodent models for mania: practical approaches. Cell Tissue Res. 2013, 354:191-201.
103. Katayama T., Hattori T., Yamada K., Matsuzaki S., Tohyama M. Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms?. Pharmacogenomics 2009, 10:1967-1978.
104. Kehoe P., Shoemaker W.J., Triano L., Callahan M., Rappolt G. Adult rats stressed as neonates show exaggerated behavioral responses to both pharmacological and environmental challenges. Behav. Neurosci. 1998, 112:116-125.
105. Kimble D.P. The effects of bilateral hippocampal lesions in rats. J. Comp. Physiol. Psychol. 1963, 56:273-283.
106. +-ATPase alpha3 sodium pump. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:18144-18149.
107. +-ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. Genes Brain Behav. 2011, 10:542-550.
108. +-ATPase alpha3 mutant mice. Genes Brain Behav. 2012, 11:436-443.
109. +-ATPase alpha3 missense mutant mice. PLoS One 2013, 8.
110. +-ATPase alpha3 mutant mice by prospective therapies for bipolar disorder: melatonin and exercise. Neuroscience 2014, 260:195-204.
111. Kittel-Schneider S., Schreck S., Ziegler C., Weissflog L., Hilscher M., Schwarz R., Schnetzler L., Neuner M., Reif A. Lithium-induced clock gene expression in lymphoblastoid cells of bipolar affective patients. Pharmacopsychiatry 2015, 48:145-149.
112. Kofman O., Li P.P., Warsh J.J. Lithium, but not carbamazepine, potentiates hyperactivity induced by intra-accumbens cholera toxin. Pharmacol. Biochem. Behav. 1998, 59:191-200.
113. Koukopoulos A., Ghaemi S.N. The primacy of mania: a reconsideration of mood disorders. Eur. Psychiatry 2009, 24:125-134.
114. Kozikowski A.P., Gaisina I.N., Yuan H., Petukhov P.A., Blond S.Y., Fedolak A., Caldarone B., McGonigle P. Structure-based design leads to the identification of lithium mimetics that block mania-like effects in rodents. Possible new GSK-3beta therapies for bipolar disorders. J. Am. Chem. Soc. 2007, 129:8328-8332.
115. Kupfer D.J. The increasing medical burden in bipolar disorder. JAMA 2005, 293:2528-2530.
116. Kuroiwa T., Bonnekoh P., Hossmann K.A. Locomotor hyperactivity and hippocampal CA1 injury after transient forebrain ischemia of gerbils. Neurosci. Lett. 1991, 122:141-144.
117. Legrand R., Fielder R. Role of dominance-submission relationships in shock-induced fighting of mice. J. Comp. Physiol. Psychol. 1973, 82:501-506.
118. Le-Niculescu H., McFarland M.J., Ogden C.A., Balaraman Y., Patel S., Tan J., Rodd Z.A., Paulus M., Geyer M.A., Edenberg H.J., Glatt S.J., Faraone S.V., Nurnberger J.I., Kuczenski R., Tsuang M.T., Niculescu A.B. Phenomic, convergent functional genomic, and biomarker studies in a stress-reactive genetic animal model of bipolar disorder and co-morbid alcoholism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008, 147b:134-166.
119. Levy N.A., Janicak P.G. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord. 2000, 2:108-119.
120. Li Y., Wolf M.E. Ibotenic acid lesions of prefrontal cortex do not prevent expression of behavioral sensitization to amphetamine. Behav. Brain Res. 1997, 84:285-289.
121. Li R., el-Mallakh R.S., Harrison L., Changaris D.G., Levy R.S. Lithium prevents ouabain-induced behavioral changes. Toward an animal model for manic depression. Molecular and Chemical Neuropathology/Sponsored by the International Society for Neurochemistry and the World Federation of Neurology and Research Groups on Neurochemistry and Cerebrospinal Fluid 1997, 31:65-72.
122. Lien R., Flaisher-Grinberg S., Cleary C., Hejny M., Einat H. Behavioral effects of Bcl-2 deficiency: implications for affective disorders. Pharmacol. Rep. 2008, 60:490-498.
123. Macedo D.S., Medeiros C.D., Cordeiro R.C., Sousa F.C., Santos J.V., Morais T.A., Hyphantis T.N., McIntyre R.S., Quevedo J., Carvalho A.F. Effects of alpha-lipoic acid in an animal model of mania induced by d-amphetamine. Bipolar Disord. 2012, 14:707-718.
124. Macedo D.S., de Lucena D.F., Queiroz A.I., Cordeiro R.C., Araujo M.M., Sousa F.C., Vasconcelos S.M., Hyphantis T.N., Quevedo J., McIntyre R.S., Carvalho A.F. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 43:230-237.
125. Machado-Vieira R., Kapczinski F., Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2004, 28:209-224.
126. Machado-Vieira R., Kapczinski F., Soares J.C. Perspectives for the development of animal models of bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2004, 28:209-224.
127. Machado-Vieira R., Andreazza A.C., Viale C.I., Zanatto V., Cereser V., da Silva Vargas R., Kapczinski F., Portela L.V., Souza D.O., Salvador M., Gentil V. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 2007, 421:33-36.
128. Maeng S., Hunsberger J.G., Pearson B., Yuan P., Wang Y., Wei Y., McCammon J., Schloesser R.J., Zhou R., Du J., Chen G., McEwen B., Reed J.C., Manji H.K. BAG1 plays a critical role in regulating recovery from both manic like and depression like behavioral impairments. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8766-8771.
129. Mak I.W., Evaniew N., Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 2014, 6:114-118.
130. Malatynska E., Knapp R.J. Dominant-submissive behavior as models of mania and depression. Neurosci. Biobehav. Rev. 2005, 29:715-737.
131. Malatynska E., Pinhasov A., Crooke J.J., Smith-Swintosky V.L., Brenneman D.E. Reduction of dominant or submissive behaviors as models for antimanic or antidepressant drug testing: technical considerations. J. Neurosci. Methods 2007, 165:175-182.
132. Maletic V., Raison C. Integrated neurobiology of bipolar disorder. Front. in Psychiatry 2014, 5:98.
133. Malkesman O., Austin D.R., Chen G., Manji H.K. Reverse translational strategies for developing animal models of bipolar disorder. Dis. Model. Mech. 2009, 2:238-245.
134. Malkoff-Schwartz S., Frank E., Anderson B., Sherrill J.T., Siegel L., Patterson D., Kupfer D.J. Stressful life events and social rhythm disruption in the onset of manic and depressive bipolar episodes: a preliminary investigation. Arch. Gen. Psychiatry 1998, 55:702-707.
135. Mansell W., Pedley R. The ascent into mania: a review of psychological processes associated with the development of manic symptoms. Clin. Psychol. Rev. 2008, 28:494-520.
136. Mansour H.A., Monk T.H., Nimgaonkar V.L. Circadian genes and bipolar disorder. Ann. Med. 2005, 37:196-205.
137. McClung C.A. Circadian rhythms and mood regulation: insights from pre-clinical models. Eur. Neuropsychopharmacol. 2011, 21(Suppl 4):S683-S693.
138. McClung C.A., Sidiropoulou K., Vitaterna M., Takahashi J.S., White F.J., Cooper D.C., Nestler E.J. Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9377-9381.
139. McInnes L.A., Service S.K., Reus V.I., Barnes G., Charlat O., Jawahar S., Lewitzky S., Yang Q., Duong Q., Spesny M., Araya C., Araya X., Gallegos A., Meza L., Molina J., Ramirez R., Mendez R., Silva S., Fournier E., Batki S.L., Mathews C.A., Neylan T., Glatt C.E., Escamilla M.A., Luo D., Gajiwala P., Song T., Crook S., Nguyen J.B., Roche E., Meyer J.M., Leon P., Sandkuijl L.A., Freimer N.B., Chen H. Fine-scale mapping of a locus for severe bipolar mood disorder on chromosome 18p11.3 in the Costa Rican population. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:11485-11490.
140. Miczek K.A., O'Donnell J.M. Intruder-evoked aggression in isolated and nonisolated mice: effects of psychomotor stimulants and L-dopa. Psychopharmacology 1978, 57:47-55.
141. Miczek K.A., Maxson S.C., Fish E.W., Faccidomo S. Aggressive behavioral phenotypes in mice. Behav. Brain Res. 2001, 125:167-181.
142. Milhiet V., Boudebesse C., Bellivier F., Drouot X., Henry C., Leboyer M., Etain B. Circadian abnormalities as markers of susceptibility in bipolar disorders. Front. Biosci. 2014, 6:120-137.
143. Mitchell P.J. Antidepressant treatment and rodent aggressive behaviour. Eur. J. Pharmacol. 2005, 526:147-162.
144. Morden B., Mullins R., Levine S. Effects of REM deprivation on the mating behavior of male rats. Psychophysiology 1968, 5:241-242.
145. Moretti M., Valvassori S.S., Varela R.B., Ferreira C.L., Rochi N., Benedet J., Scaini G., Kapczinski F., Streck E.L., Zugno A.I., Quevedo J. Behavioral and neurochemical effects of sodium butyrate in an animal model of mania. Behav. Pharmacol. 2011, 22:766-772.
146. Nakane H., Ooboshi H., Ibayashi S., Yao H., Sadoshima S., Fujishima M. Isradipine, a calcium channel blocker, attenuates the ischemia-induced release of dopamine but not glutamate in rats. Neurosci. Lett. 1995, 188:151-154.
147. Nestler E.J., Hyman S.E. Animal models of neuropsychiatric disorders. Nat. Neurosci. 2010, 13:1161-1169.
148. O'Donnell K.C., Gould T.D. The behavioral actions of lithium in rodent models: leads to develop novel therapeutics. Neurosci. Biobehav. Rev. 2007, 31:932-962.
149. Paszti-Gere E., Jakus J. Protein phosphatases but not reactive oxygen species play functional role in acute amphetamine-mediated dopamine release. Cell Biochem. Biophys. 2013, 66:831-841.
150. Perez J., Tardito D., Mori S., Racagni G., Smeraldi E., Zanardi R. Abnormalities of cyclic adenosine monophosphate signaling in platelets from untreated patients with bipolar disorder. Arch. Gen. Psychiatry 1999, 56:248-253.
151. Post R.M. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci. Biobehav. Rev. 2007, 31:858-873.
152. Post R.M., Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br. J. Psychiatry 2013, 202:172-176.
153. Post R.M., Weiss S.R. Sensitization, kindling, and anticonvulsants in mania. J. Clin. Psychiatry 1989, 50:23-30. (Suppl.).
154. Post R.M., Weiss S.R. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol. Neurobiol. 1996, 13:33-60.
155. Post R.M., Weiss S.R. Sensitization and kindling phenomena in mood, anxiety, and obsessive-compulsive disorders: the role of serotonergic mechanisms in illness progression. Biol. Psychiatry 1998, 44:193-206.
156. Post R.M., Uhde T.W., Putnam F.W., Ballenger J.C., Berrettini W.H. Kindling and carbamazepine in affective illness. J. Nerv. Ment. Dis. 1982, 170:717-731.
157. Post R.M., Susan R., Weiss B. Sensitization, kindling, and carbamazepine: an update on their implications for the course of affective illness. Pharmacopsychiatry 1992, 25:41-43.
158. Post R.M., Leverich G.S., Xing G., Weiss R.B. Developmental vulnerabilities to the onset and course of bipolar disorder. Dev. Psychopathol. 2001, 13:581-598.
159. Powell S.B., Young J.W., Ong J.C., Caron M.G., Geyer M.A. Atypical antipsychotics clozapine and quetiapine attenuate prepulse inhibition deficits in dopamine transporter knockout mice. Behav. Pharmacol. 2008, 19:562-565.
160. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., Daneels G., Bouwknecht J.A., Steckler T. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. J. Neurosci. 2006, 26:9022-9029.
161. Queiroz A.I., de Araujo M.M., da Silva Araujo T., de Souza G.C., Cavalcante L.M., de Jesus Souza Machado M., de Lucena D.F., Quevedo J., Macedo D. GBR 12909 administration as an animal model of bipolar mania: time course of behavioral, brain oxidative alterations and effect of mood stabilizing drugs. Metab. Brain Dis. 2015.
162. Ralph-Williams R.J., Paulus M.P., Zhuang X., Hen R., Geyer M.A. Valproate attenuates hyperactive and perseverative behaviors in mutant mice with a dysregulated dopamine system. Biol. Psychiatry 2003, 53:352-359.
163. Rao J.S., Keleshian V.L., Klein S., Rapoport S.I. Epigenetic modifications in frontal cortex from Alzheimer's disease and bipolar disorder patients. Translat. Psychiatry 2012, 2.
164. Rao J.S., Kellom M., Reese E.A., Rapoport S.I., Kim H.W. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J. Affect. Disord. 2012, 136:63-71.
165. Razafsha M., Behforuzi H., Harati H., Wafai R.A., Khaku A., Mondello S., Gold M.S., Kobeissy F.H. An updated overview of animal models in neuropsychiatry. Neuroscience 2013, 240:204-218.
166. Redrobe J.P., Nielsen A.N. Effects of neuronal Kv7 potassium channel activators on hyperactivity in a rodent model of mania. Behav. Brain Res. 2009, 198:481-485.
167. Rezin G.T., Furlanetto C.B., Scaini G., Valvassori S.S., Goncalves C.L., Ferreira G.K., Jeremias I.C., Resende W.R., Cardoso M.R., Varela R.B., Quevedo J., Streck E.L. Fenproporex increases locomotor activity and alters energy metabolism, and mood stabilizers reverse these changes: a proposal for a new animal model of mania. Mol. Neurobiol. 2014, 49:877-892.
168. Ricke A.K., Snook R.J., Anand A. Induction of prolonged mania during ketamine therapy for reflex sympathetic dystrophy. Biol. Psychiatry 2011, 70:e13-e14.
169. Riegel R.E., Valvassori S.S., Elias G., Reus G.Z., Steckert A.V., de Souza B., Petronilho F., Gavioli E.C., Dal-Pizzol F., Quevedo J. Animal model of mania induced by ouabain: evidence of oxidative stress in submitochondrial particles of the rat brain. Neurochem. Int. 2009, 55:491-495.
170. Riegel R.E., Valvassori S.S., Moretti M., Ferreira C.L., Steckert A.V., de Souza B., Dal-Pizzol F., Quevedo J. Intracerebroventricular ouabain administration induces oxidative stress in the rat brain. Int. J. Dev. Neurosci. 2010, 28:233-237.
171. Robinson T.E., Becker J.B., Moore C.J., Castaneda E., Mittleman G. Enduring enhancement in frontal cortex dopamine utilization in an animal model of amphetamine psychosis. Brain Res. 1985, 343:374-377.
172. Roybal K., Theobold D., Graham A., DiNieri J.A., Russo S.J., Krishnan V., Chakravarty S., Peevey J., Oehrlein N., Birnbaum S., Vitaterna M.H., Orsulak P., Takahashi J.S., Nestler E.J., Carlezon W.A., McClung C.A. Mania-like behavior induced by disruption of CLOCK. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6406-6411.
173. Ruktanonchai D.J., El-Mallakh R.S., Li R., Levy R.S. Persistent hyperactivity following a single intracerebroventricular dose of ouabain. Physiol. Behav. 1998, 63:403-406.
174. Rygula R., Szczech E., Kregiel J., Golebiowska J., Kubik J., Popik P. Cognitive judgment bias in the psychostimulant-induced model of mania in rats. Psychopharmacology 2015, 232:651-660.
175. Saul M.C., Gessay G.M., Gammie S.C. A new mouse model for mania shares genetic correlates with human bipolar disorder. PLoS One 2012, 7.
176. Schaeffer J.C., Cho A.K., Fischer J.F. Inhibition of synaptosomal accumulation of l-norepinephrine II: N-aryloxyalkylphentermines, quaternary d-amphetamines, and 3-aryloxypropylamines. J. Pharm. Sci. 1976, 65:122-126.
177. Scheuing L., Chiu C.T., Liao H.M., Chuang D.M. Antidepressant mechanism of ketamine: perspective from preclinical studies. Front. Neurosci. 2015, 9:249.
178. Schulze T.G., Buervenich S., Badner J.A., Steele C.J., Detera-Wadleigh S.D., Dick D., Foroud T., Cox N.J., MacKinnon D.F., Potash J.B., Berrettini W.H., Byerley W., Coryell W., DePaulo J.R., Gershon E.S., Kelsoe J.R., McInnis M.G., Murphy D.L., Reich T., Scheftner W., Nurnberger J.I., McMahon F.J. Loci on chromosomes 6q and 6p interact to increase susceptibility to bipolar affective disorder in the national institute of mental health genetics initiative pedigrees. Biol. Psychiatry 2004, 56:18-23.
179. Serra G., Koukopoulos A., De Chiara L., Koukopoulos A.E., Tondo L., Girardi P., Baldessarini R.J., Serra G. Three-year, naturalistic, mirror-image assessment of adding memantine to the treatment of 30 treatment-resistant patients with bipolar disorder. J. Clin. Psychiatry 2015, 76:e91-e97.
180. Serretti A., Drago A., De Ronchi D. Lithium pharmacodynamics and pharmacogenetics: focus on inositol mono phosphatase (IMPase), inositol poliphosphatase (IPPase) and glycogen synthase kinase 3 beta (GSK-3 beta). Curr. Med. Chem. 2009, 16:1917-1948.
181. Shaldubina A., Einat H., Szechtman H., Shimon H., Belmaker R.H. Preliminary evaluation of oral anticonvulsant treatment in the quinpirole model of bipolar disorder. J. Neural Transm. 2002, 109:433-440.
182. Shaltiel G., Maeng S., Malkesman O., Pearson B., Schloesser R.J., Tragon T., Rogawski M., Gasior M., Luckenbaugh D., Chen G., Manji H.K. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol. Psychiatry 2008, 13:858-872.
183. Sharma A.N., Bauer I.E., Sanches M., Galvez J.F., Zunta-Soares G.B., Quevedo J., Kapczinski F., Soares J.C. Common biological mechanisms between bipolar disorder and type 2 diabetes: focus on inflammation. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2014, 54:289-298.
184. Sidor M.M., Spencer S.M., Dzirasa K., Parekh P.K., Tye K.M., Warden M.R., Arey R.N., Enwright J.F., Jacobsen J.P., Kumar S., Remillard E.M., Caron M.G., Deisseroth K., McClung C.A. Daytime spikes in dopaminergic activity drive rapid mood-cycling in mice. Mol. Psychiatry 2015, 5.
185. Steckert A.V., Valvassori S.S., Varela R.B., Mina F., Resende W.R., Bavaresco D.V., Ornell F., Dal-Pizzol F., Quevedo J. Effects of sodium butyrate on oxidative stress and behavioral changes induced by administration of D-AMPH. Neurochem. Int. 2013, 62:425-432.
186. Stertz L., Fries G.R., Aguiar B.W., Pfaffenseller B., Valvassori S.S., Gubert C., Ferreira C.L., Moretti M., Cereser K.M., Kauer-Sant'Anna M. Histone deacetylase activity and brain-derived neurotrophic factor (BDNF) levels in a pharmacological model of mania. Rev. Bras. Psiquiatr. 2014, 36:39-46.
187. Sui L., Song X.J., Ren J., Ju L.H., Wang Y. Intracerebroventricular administration of ouabain alters synaptic plasticity and dopamine release in rat medial prefrontal cortex. J. Neural Transm. 2013, 120:1191-1199.
188. Swerdlow N.R., Halim N., Hanlon F.M., Platten A., Auerbach P.P. Lesion size and amphetamine hyperlocomotion after neonatal ventral hippocampal lesions: more is less. Brain Res. Bull. 2001, 55:71-77.
189. Szabo S.T., Machado-Vieira R., Yuan P., Wang Y., Wei Y., Falke C., Cirelli C., Tononi G., Manji H.K., Du J. Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania. Neuropharmacology 2009, 56:47-55.
190. Takuma K., Maeda Y., Ago Y., Ishihama T., Takemoto K., Nakagawa A., Shintani N., Hashimoto H., Baba A., Matsuda T. An enriched environment ameliorates memory impairments in PACAP-deficient mice. Behav. Brain Res. 2014, 272:269-278.
191. Teixeira A.L., Quevedo J. Animal models in psychiatry. Rev. Bras. Psiquiatr. 2013, 35(Suppl 2):S73-S74.
192. Toker L., Bersudsky Y., Plaschkes I., Chalifa-Caspi V., Berry G.T., Buccafusca R., Moechars D., Belmaker R.H., Agam G. Inositol-related gene knockouts mimic lithium's effect on mitochondrial function. Neuropsychopharmacology 2014, 39:319-328.
193. Trevizol F., Roversi K., Dias V.T., Roversi K., Pase C.S., Barcelos R.C., Benvegnu D.M., Kuhn F.T., Dolci G.S., Ross D.H., Veit J.C., Piccolo J., Emanuelli T., Burger M.E. Influence of lifelong dietary fats on the brain fatty acids and amphetamine-induced behavioral responses in adult rat. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2013, 45:215-222.
194. Valvassori S.S., Budni J., Varela R.B., Quevedo J. Contributions of animal models to the study of mood disorders. Rev. Bras. Psiquiatr. 2013, 35(Suppl 2):S121-S131.
195. Valvassori S.S., Bavaresco D.V., Budni J., Bobsin T.S., Goncalves C.L., de Freitas K.V., Streck E.L., Quevedo J. Effects of tamoxifen on tricarboxylic acid cycle enzymes in the brain of rats submitted to an animal model of mania induced by amphetamine. Psychiatry Res. 2014, 215:483-487.
196. van Enkhuizen J., Geyer M.A., Kooistra K., Young J.W. Chronic valproate attenuates some, but not all, facets of mania-like behaviour in mice. Int. J. Neuropsychopharmacol. 2013, 16:1021-1031.
197. van Enkhuizen J., Henry B.L., Minassian A., Perry W., Milienne-Petiot M., Higa K.K., Geyer M.A., Young J.W. Reduced dopamine transporter functioning induces high-reward risk-preference consistent with bipolar disorder. Neuropsychopharmacology 2014, 39:3112-3122.
198. Vassout A., Veenstra S., Hauser K., Ofner S., Brugger F., Schilling W., Gentsch C. NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats. Regul. Pept. 2000, 96:7-16.
199. Verwer R.W., Van Vulpen E.H., Van Uum J.F. Postnatal development of amygdaloid projections to the prefrontal cortex in the rat studied with retrograde and anterograde tracers. J. Comp. Neurol. 1996, 376:75-96.
200. Wang D., Corbett D. Cerebral ischemia, locomotor activity and spatial mapping. Brain Res. 1990, 533:78-82.
201. Weeke A., Juel K., Vaeth M. Cardiovascular death and manic-depressive psychosis. J. Affect. Disord. 1987, 13:287-292.
202. Wilkinson L.S., Mittleman G., Torres E., Humby T., Hall F.S., Robbins T.W. Enhancement of amphetamine-induced locomotor activity and dopamine release in nucleus accumbens following excitotoxic lesions of the hippocampus. Behav. Brain Res. 1993, 55:143-150.
203. Willner P. The validity of animal models of depression. Psychopharmacology 1984, 83:1-16.
204. Wolterink G., Daenen L.E., Dubbeldam S., Gerrits M.A., van Rijn R., Kruse C.G., Van Der Heijden J.A., Van Ree J.M. Early amygdala damage in the rat as a model for neurodevelopmental psychopathological disorders. Eur. Neuropsychopharmacol. 2001, 11:51-59.
205. Wong P., Chang C.C., Marx C.E., Caron M.G., Wetsel W.C., Zhang X. Pregnenolone rescues schizophrenia-like behavior in dopamine transporter knockout mice. PLoS One 2012, 7.
206. Yang C.R., Bai Y.Y., Ruan C.S., Zhou H.F., Liu D., Wang X.F., Shen L.J., Zheng H.Y., Zhou X.F. Enhanced aggressive behaviour in a mouse model of depression. Neurotox. Res. 2015, 27:129-142.
207. Young J.W., Minassian A., Paulus M.P., Geyer M.A., Perry W. A reverse-translational approach to bipolar disorder: rodent and human studies in the Behavioral Pattern Monitor. Neurosci. Biobehav. Rev. 2007, 31:882-896.
208. Young J.W., Henry B.L., Geyer M.A. Predictive animal models of mania: hits, misses and future directions. Br. J. Pharmacol. 2011, 164:1263-1284.
209. Young J.W., van Enkhuizen J., Winstanley C.A., Geyer M.A. Increased risk-taking behavior in dopamine transporter knockdown mice: further support for a mouse model of mania. J. Psychopharmacol. 2011, 25:934-943.
210. Zhuang X., Oosting R.S., Jones S.R., Gainetdinov R.R., Miller G.W., Caron M.G., Hen R. Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1982-1987.
211. Zugno A.I., Chipindo H., Canever L., Budni J., Alves de Castro A., Bittencourt de Oliveira M., Heylmann A.S., Gomes Wessler P., da Rosa Silveira F., Damazio L.S., Mastella G.A., Kist L.W., Bogo M.R., Quevedo J., Gama C.S. Omega-3 fatty acids prevent the ketamine-induced increase in acetylcholinesterase activity in an animal model of schizophrenia. Life Sci. 2015, 121:65-69.
212. Zugno A.I., Pacheco F.D., Budni J., de Oliveira M.B., Canever L., Heylmann A.S., Wessler P.G., da Rosa Silveira F., Mastella G.A., Goncalves C.L., Freitas K.V., de Castro A.A., Streck E.L., Quevedo J. Maternal deprivation disrupts mitochondrial energy homeostasis in the brain of rats subjected to ketamine-induced schizophrenia. Metab. Brain Dis. 2015, 30:1043-1053.